vs
CVB FINANCIAL CORP（CVBF）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是CVB FINANCIAL CORP的1.6倍（$219.9M vs $133.8M），CVB FINANCIAL CORP同比增速更快（8.4% vs 2.0%），CVB FINANCIAL CORP自由现金流更多（$217.3M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.8%）
CVB金融集团是一家美国银行控股公司，运营公民商业银行，主要服务加利福尼亚州市场，面向中小企业、专业机构及个人客户提供商业银行、个人银行、财富管理等多元金融服务，核心业务包含商业贷款、存款账户、资产管理等。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CVBF vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$133.8M
营收增速更快
CVBF
高出6.4%
2.0%
自由现金流更多
CVBF
多$200.5M
$16.8M
两年增速更快
OFIX
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $133.8M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 55.6% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 8.4% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.41 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVBFOFIX
| Q4 25 | $133.8M | $219.9M | ||
| Q3 25 | $128.6M | $205.6M | ||
| Q2 25 | $126.4M | $203.1M | ||
| Q1 25 | $126.7M | $193.6M | ||
| Q4 24 | $123.5M | $215.7M | ||
| Q3 24 | $126.5M | $196.6M | ||
| Q2 24 | $125.3M | $198.6M | ||
| Q1 24 | $126.6M | $188.6M |
净利润CVBFOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $52.6M | $-22.8M | ||
| Q2 25 | $50.6M | $-14.1M | ||
| Q1 25 | $51.1M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $51.2M | $-27.4M | ||
| Q2 24 | $50.0M | $-33.4M | ||
| Q1 24 | $48.6M | $-36.0M |
毛利率CVBFOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CVBFOFIX
| Q4 25 | 55.6% | 0.2% | ||
| Q3 25 | 53.7% | -8.3% | ||
| Q2 25 | 54.4% | -7.9% | ||
| Q1 25 | 54.9% | -25.2% | ||
| Q4 24 | 55.1% | -5.3% | ||
| Q3 24 | 53.5% | -9.6% | ||
| Q2 24 | 54.9% | -12.5% | ||
| Q1 24 | 52.8% | -15.6% |
净利率CVBFOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 40.9% | -11.1% | ||
| Q2 25 | 40.0% | -6.9% | ||
| Q1 25 | 40.3% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 40.5% | -13.9% | ||
| Q2 24 | 39.9% | -16.8% | ||
| Q1 24 | 38.4% | -19.1% |
每股收益（稀释后）CVBFOFIX
| Q4 25 | $0.41 | $-0.05 | ||
| Q3 25 | $0.38 | $-0.57 | ||
| Q2 25 | $0.37 | $-0.36 | ||
| Q1 25 | $0.36 | $-1.35 | ||
| Q4 24 | $0.36 | $-0.76 | ||
| Q3 24 | $0.37 | $-0.71 | ||
| Q2 24 | $0.36 | $-0.88 | ||
| Q1 24 | $0.35 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $376.4M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $450.0M |
| 总资产 | $15.6B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVBFOFIX
| Q4 25 | $376.4M | $82.0M | ||
| Q3 25 | $783.9M | $62.9M | ||
| Q2 25 | $738.6M | $65.6M | ||
| Q1 25 | $529.1M | $58.0M | ||
| Q4 24 | $204.7M | $83.2M | ||
| Q3 24 | $453.5M | $30.1M | ||
| Q2 24 | $844.2M | $26.4M | ||
| Q1 24 | $949.6M | $27.0M |
总债务CVBFOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益CVBFOFIX
| Q4 25 | $2.3B | $450.0M | ||
| Q3 25 | $2.3B | $442.5M | ||
| Q2 25 | $2.2B | $458.3M | ||
| Q1 25 | $2.2B | $458.3M | ||
| Q4 24 | $2.2B | $503.1M | ||
| Q3 24 | $2.2B | $525.9M | ||
| Q2 24 | $2.1B | $546.0M | ||
| Q1 24 | $2.1B | $570.3M |
总资产CVBFOFIX
| Q4 25 | $15.6B | $850.6M | ||
| Q3 25 | $15.7B | $832.6M | ||
| Q2 25 | $15.4B | $837.2M | ||
| Q1 25 | $15.3B | $823.1M | ||
| Q4 24 | $15.2B | $893.3M | ||
| Q3 24 | $15.4B | $867.9M | ||
| Q2 24 | $16.2B | $882.0M | ||
| Q1 24 | $16.5B | $906.0M |
负债/权益比CVBFOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $221.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $217.3M | $16.8M |
| 自由现金流率自由现金流/营收 | 162.4% | 7.6% |
| 资本支出强度资本支出/营收 | 3.0% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $391.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CVBFOFIX
| Q4 25 | $221.4M | $27.7M | ||
| Q3 25 | $81.5M | $12.4M | ||
| Q2 25 | $53.1M | $11.6M | ||
| Q1 25 | $41.9M | $-18.4M | ||
| Q4 24 | $249.8M | $23.7M | ||
| Q3 24 | $71.4M | $11.7M | ||
| Q2 24 | $26.1M | $9.0M | ||
| Q1 24 | $77.5M | $-18.6M |
自由现金流CVBFOFIX
| Q4 25 | $217.3M | $16.8M | ||
| Q3 25 | $80.7M | $2.5M | ||
| Q2 25 | $52.3M | $4.5M | ||
| Q1 25 | $41.2M | $-25.1M | ||
| Q4 24 | $244.6M | $15.2M | ||
| Q3 24 | $70.2M | $6.3M | ||
| Q2 24 | $24.4M | $-360.0K | ||
| Q1 24 | $77.3M | $-29.1M |
自由现金流率CVBFOFIX
| Q4 25 | 162.4% | 7.6% | ||
| Q3 25 | 62.8% | 1.2% | ||
| Q2 25 | 41.4% | 2.2% | ||
| Q1 25 | 32.5% | -13.0% | ||
| Q4 24 | 198.0% | 7.0% | ||
| Q3 24 | 55.5% | 3.2% | ||
| Q2 24 | 19.5% | -0.2% | ||
| Q1 24 | 61.1% | -15.4% |
资本支出强度CVBFOFIX
| Q4 25 | 3.0% | 4.9% | ||
| Q3 25 | 0.7% | 4.8% | ||
| Q2 25 | 0.7% | 3.5% | ||
| Q1 25 | 0.5% | 3.5% | ||
| Q4 24 | 4.2% | 4.0% | ||
| Q3 24 | 1.0% | 2.7% | ||
| Q2 24 | 1.4% | 4.7% | ||
| Q1 24 | 0.1% | 5.6% |
现金转化率CVBFOFIX
| Q4 25 | — | — | ||
| Q3 25 | 1.55× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 0.82× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.39× | — | ||
| Q2 24 | 0.52× | — | ||
| Q1 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVBF
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
